Oncotelic Therapeutics Inc (OTLC)

$OTLC another financing… https://tipranks.onelink.me/WJho/141idj3x

Oncotelic Therapeutics, Inc. (OTCQB: $OTLC ) presents at the OTCQB Virtual Investor Conference at 2:30 PM ET on Thursday, August 6, 2026. The OTCQB Virtual Investor Conference is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-august-5th-and-6th-otcqb-virtual-investor-conference To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5436153/oncotelic-therapeutics-inc-otcqb-otlc?utm_source=b2i&utm_medium=marketing&utm_campaign=0806AugOTCQBVIC Request a one-on-one meeting: https://app.axleaccess.com/public/events/a423dcfc-dcb6-434d-a717-92e0c2bd482c?token=bed16a45-7c55-4efb-a23e-3321c2e5a7e0 Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products, with a stated mission to address high-unmet-need cancers and rare pediatric indications with late-stage therapeutic candidates. Beyond its internal programs, the Company licenses and co-develops select drug candidates through joint ventures, owns 45% of the GMP Bio joint venture, and develops PDAOAI, its proprietary artificial intelligence platform for drug discovery, cleanroom automation, and AI-assisted GMP manufacturing. Learn more at [www.oncotelic.com/investors](https://www.oncotelic.com/investors/). Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. @B2iDigital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

Oncotelic Therapeutics, Inc. (OTCQB: $OTLC ) presents at the OTCQB Virtual Investor Conference at 2:30 PM ET on Thursday, August 6, 2026. The OTCQB Virtual Investor Conference is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-august-5th-and-6th-otcqb-virtual-investor-conference To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5436153/oncotelic-therapeutics-inc-otcqb-otlc?utm_source=b2i&utm_medium=marketing&utm_campaign=0806AugOTCQBVIC Request a one-on-one meeting: https://app.axleaccess.com/public/events/a423dcfc-dcb6-434d-a717-92e0c2bd482c?token=bed16a45-7c55-4efb-a23e-3321c2e5a7e0 Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products, with a stated mission to address high-unmet-need cancers and rare pediatric indications with late-stage therapeutic candidates. Beyond its internal programs, the Company licenses and co-develops select drug candidates through joint ventures, owns 45% of the GMP Bio joint venture, and develops PDAOAI, its proprietary artificial intelligence platform for drug discovery, cleanroom automation, and AI-assisted GMP manufacturing. Learn more at [www.oncotelic.com/investors](https://www.oncotelic.com/investors/). Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. @B2iDigital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

$AMIX $OTLC $RDW

$OTLC when can we expect an update on the OT-101 trial? It's been forever since they initiated the study.

NetworkNewsBreaks – $OTLC to Present at OTCQB Virtual Investor Conference https://ibn.fm/Ennf5

$OTLC — OTCQB Virtual Investor Conference Agenda Announced for August 5 & 6 https://finance.yahoo.com/markets/stocks/articles/otcqb-virtual-investor-conference-agenda-123500488.html

$OTLC — Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus) https://finance.yahoo.com/healthcare/articles/oncotelic-announces-peer-reviewed-publication-133000651.html

BioMedNewsBreaks — $OTLC Publishes Preclinical Data Supporting IV Cancer Therapy https://ibn.fm/hocuZ

$OTLC - yeah, all that previous- its a bad look for the co to release that one oress on the 249mm estimate number- For “fair value of GMP Bio…News like that needs to stop… until something is really being sold or they can legitimately add sone big pharma names into their associations- without any real doubt by investor/trading community